What is the Market's View on Revance Therapeutics Inc (RVNC) Stock's Price and Volume Trends Monday?

The market has been high on Revance Therapeutics Inc (RVNC) stock recently. RVNC gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Revance Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RVNC!

See Full RVNC Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With RVNC Stock Today?

Revance Therapeutics Inc (RVNC) stock is up 4.73% while the S&P 500 is lower by -0.01% as of 11:08 AM on Monday, Mar 21. RVNC has gained $0.83 from the previous closing price of $17.54 on volume of 393,050 shares. Over the past year the S&P 500 is up 13.25% while RVNC is lower by -36.96%. RVNC lost -$4.17 per share in the over the last 12 months.

More About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Click Here to get the full Stock Report for Revance Therapeutics Inc stock.